Stereoselective Formation and Metabolism of 4-Hydroxy-Retinoic Acid

Enantiomers by Cytochrome P450 Enzymes*

Jakob A. Shimshoni,¹ Arthur G. Roberts,^{2,3} Michele Scian,⁴ Ariel R. Topletz,¹ Sean A. Blankert,³ James R. Halpert,² Wendel L. Nelson⁴ and Nina Isoherranen¹

¹Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA ²Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA ³Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA ⁴Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, WA

* Running title: Stereoselective retinoic acid metabolism

To whom correspondence should be addressed: Nina Isoherranen, PhD, Department of Pharmaceutics, Box 357610, University of Washington, Seattle, WA 98195, United States. Tel.: +1-206-543-2517; fax: +1-206-543-3204. E-mail address: ni2@u.washington.edu

Keywords: Retinoic acid, Cytochrome P450, stereoselectivity

Background: CYP26A1 is a critical enzyme in the metabolism of all-trans retinoic acid (*at*RA).

Results: CYP26A1 metabolizes atRA stereoselectively to (4S)-OH-RA, which corresponds to atRA orientation within the CYP26A1 active site.

Conclusion: Preference for (4S)-OH-RA is conserved in *at*RA metabolism and in elimination of 4-OH-RA.

Significance: Determination of stereoselectivity in *at*RA metabolism is important for better understanding of retinoid biology and CYP26A1 biochemistry.

SUMMARY

all-trans-Retinoic acid (atRA), the major active metabolite of vitamin A, plays a role in many biological processes, maintenance including of epithelia. immunity, and fertility and regulation of apoptosis and cell differentiation. atRA is metabolized mainly by CYP26A1, but other P450 enzymes such as CYP2C8 and CYP3As also contribute to atRA 4hydroxylation. Although the primary

metabolite of atRA, 4-OH-RA, possesses a chiral center, the stereochemical course of atRA 4-hydroxylation has not been studied previously. (4S)- and (4R)-OH-RA enantiomers were synthesized and separated by chiral column HPLC. **CYP26A1** was found to form This predominantly (4S)-OH-RA. stereoselectivity was rationalized via docking of atRA in the active site of a CYP26A1 homology model. The docked structure showed a well-defined niche for atRA within the active site and a specific orientation of the β -ionone ring above the plane of the heme consistent with stereoselective abstraction of the hydrogen atom from the pro-(S)-position. In contrast to CYP26A1, CYP3A4 formed the 4-OH-RA enantiomers in a 1:1 ratio and CYP3A5 preferentially formed (4R)-**OH-RA.** Interestingly, CYP3A7 and CYP2C8 preferentially formed (4S)-OH-RA from atRA. Both (4S)- and (4R)-OH-RA were substrates of CYP26A1 but (4S)-**OH-RA** was cleared three-fold faster than (4R)-OH-RA. In addition, 4-oxo-RA was

Downloaded from www.jbc.org at CALIFORNIA STATE UNIV FRESNO, on October 24, 2012

formed from (4R)-OH-RA but not from (4S)-OH-RA by CYP26A1. Overall, these findings show that (4S)-OH-RA is preferred over (4R)-OH-RA by the enzymes regulating *at*RA homeostasis. The stereoselectivity observed in CYP26A1 function will aid in better understanding of the active site features of the enzyme and the disposition of biologically active retinoids.

all-trans-Retinoic acid (atRA) is the major biologically active metabolite of vitamin A (retinol). It is an essential component of signaling networks in chordates. During embryonic and fetal development atRA regulates cell differentiation, and during adult life it is important for maintaining healthy epithelia, immunity, fertility and in regulating cell proliferation (1). atRA also plays a role in neurogenesis in adults and in cell survival (2), and it contributes to regulation of glucose homeostasis (3). These effects of atRA result mainly from its binding to the three nuclear retinoic acid receptors (RAR α , RAR β and RAR γ) that are activated by *at*RA resulting in induction of gene transcription (4).

Therapeutically *at*RA (Tretinoin[®]), 13-*cis*retinoic acid (Isotretinoin[®]) and 9-cisretinoic acid (Alitretinoin[®]) are used in the treatment of various cancers and skin diseases (4). All three RA isomers are cleared mainly by metabolic oxidation and glucuronidation (5-8). The main circulating metabolite of 13-cis-RA and atRA detected in human plasma is 4-oxo-RA (9,10), the subsequent metabolite of 4-OH-RA. 4-OH-RA is the primary oxidized metabolite of atRA. It is formed by several cytochrome P450 enzymes including CYP26s, CYP3As and CYP2C8 (6-8,11-13). Of these P450 enzymes, CYP26A1 appears to be the main isoform responsible for both *at*RA clearance and for formation of 4-OH-RA in human liver (13). CYP26A1 and CYP26B1 have also been identified as the key enzymes that regulate *at*RA metabolism in other tissues during development and in adulthood (11,12,14,15).

The oxidative metabolism of *at*RA by CYP26A1 is believed to be the first step in its degradation and inactivation (14). However, the main atRA metabolites, 4-OH-RA and 4-oxo-RA, also bind to the three RAR isoforms with affinities similar to *at*RA (16), and they induce gene inhibit transcription. proliferation and induce differentiation in various atRA susceptible cell lines and models (17,18). Formation of metabolites from *at*RA by CYP26A1 also appears to be required for differentiation of P19 EC cells into neurons, and to atRA induced differentiation of embryonic stem cells (19,20). These data suggest that metabolites of atRA may be important in retinoid function when sufficient concentrations are reached in vivo. However, transgenic animal studies have shown that CYP26 enzymes are required for removal of *at*RA rather than for formation active metabolites during of mouse development (21).

The hydroxylation of *at*RA to 4-OH-RA results in the formation of a chiral center (Figure 1) but all studies characterizing formation of 4-OH-RA and its activity have been conducted using racemic 4-OH-RA. Since formation of 4-OH-RA could be stereospecific and the biological activity may reside in a single 4-OH-RA enantiomer, understanding of the functional role(s) of atRA metabolites requires characterization of the stereochemical course of metabolism. In addition, stereospecificity of the enzymes involved in RA biotransformation may help in better understanding of the structurefunction of the proteins involved in regulating RA homeostasis.

Stereoselectivity appears to be a key characteristic of retinoid biotransformation. Hydroxylation of retinol in F9 cells results predominantly in the formation of (4S)-OH- retinol (22), and in the firefly squid, the visual pigment is (4R)-OH-retinal (23). The mouse and zebrafish retinol saturase selectively forms (R)-*all-trans*-13,14-dihydroretinol, and the biological activity (adipocyte differentiation and RAR activation) of this product resides in the (R)-enantiomer (24).

Based on the observed stereoselectivity associated with other retinoids and the tight binding of atRA to CYP26A1, it was hypothesized that formation of 4-OH-RA by CYP26A1 would be stereoselective. To test this hypothesis, a chiral column HPLC method was developed to separate the 4-OH-RA enantiomers, standards of the (4S)- and (4R)-OH-RA enantiomers were synthesized, and the formation of 4-OH-RA enantiomers by CYP26A1, CYP2C8 and CYP3A4 isoforms was characterized. The formation of 4-OH-RA by CYP26A1 was stereoselective resulting in formation of (4S)-OH-RA whereas the other P450s formed both 4-OH-RA enantiomers with varying stereoselectivities. (4S)-OH-RA was also a better substrate of CYP26A1 than (4R)-OH-RA resulting in formation of different metabolites and suggesting that the observed stereoselectivity may have broader biological importance.

EXPERIMENTAL PROCEDURES

Separation of (4S)- and (4R)-OH-RA enantiomers- The 4-OH-RA enantiomers separated using were an Agilent Technologies (Palo Alto, CA) 1200 series HPLC system equipped with a Chiralcel OD-RH column (5 µm, 2.1 x 150 mm), an temperature controlled Agilent autosampler, a multiple wavelength detector and HP Chemstation software. The mobile phase flow was 0.17 ml/min. A linear gradient from initial 50:50 water:acetonitrile for 14 min to 20:80 over 10 min was used, followed by 20:80 water: acetonitrile for 10 Analytes quantified min. were by determining the UV absorbance at 360 nm.

Protein expression and enzymatic of *4-OH-RA* formation enantiomers-CYP26A1 microsomes were prepared and rat reductase was expressed and purified as previously described (13,25). CYP3A4, CYP3A5, CYP3A7 and CYP2C8 were purchased from BD Gentest and were coexpressed with P450 reductase and cytochrome b₅. All incubations were conducted in 100 mM potassium phosphate buffer (pH=7.4) at 37 °C and initiated by addition of NADPH (1 mМ final concentration) (Sigma-Aldrich, St. Louis, MO). The reactions were quenched and metabolites extracted using ethyl acetate as described previously (25, 26).The stereoselective formation of 4-OH-RA by P450 enzymes (5 nM) was characterized with 10 nM-40 uM atRA as a substrate. P450 reductase (10 nM) was added to incubations with CYP26A1. The product formation data were analyzed and the Michaelis-Menten equation was fitted to the data using GraphPad Prism v.5 (La Jolla, CA).

Metabolism of (4R)- and (4S)-OH-RA by The metabolites formed from CYP26A1-(4R)-OH-RA and (4S)-OH-RA by CYP26A1 were identified using LC-MS/MS conditions identical to those previously reported for racemic 4-OH-RA (15). Five pmoles of CYP26A1 and 10 pmoles of P450 reductase were incubated with 1 µM of each enantiomer in 1 mL of potassium phosphate (100 mM, pH 7.4) buffer, and samples were extracted using ethyl acetate as described (15).

The time course of (4R)-OH-RA and (4S)-OH-RA depletion by CYP26A1 was determined at six substrate concentrations between 2 and 250 nM using a P450 reductase to CYP26A1 ratio of 2:1 (2 pmol/mL P450 in each incubation), in 100 mM potassium phosphate buffer (pH=7.4) at 37 °C. All incubations were conducted under

red light in triplicate and the experiments were repeated three times on separate days. The reactions were initiated by addition of NADPH (1 mM final concentration). At 0.5, 1, 2, and 5 min, 0.5 mL aliquots were collected and quenched with 3 mL of cold ethyl acetate. For a separate experiment at 2.5nM substrate concentration, 1 mL aliquots were collected at 0.5, 1, 1.5 and 2 min. As an internal standard, 20 µL of a 2.5 µM solution of 4-oxo-RA-D₃ (Toronto Research Chemicals, North York, Ontario) in ethanol was added, and samples were extracted as previously described (15). 4-OH-RA enantiomers were analyzed using an AB Sciex API 5500 Q/LIT mass spectrometer equipped with an Agilent 1290 Infinity UHPLC and an Agilent Zorbax C18 column (3.5 µm, 2.1 mm x 100 mm). The analytes were separated using a 10 min linear gradient from initial 5:95 acetonitrile: 0.1% aqueous formic acid to a final 95:5 acetonitrile: 0.1% aqueous formic acid. Analytes were detected using positive ion electrospray mass spectrometry with the declustering potential set to 80, collision energy to 33 (4-OH-RA) and 35 (4-oxo-RA- D_3), and collision exit potential to 13 (4-OH-RA) and 2 (4-oxo-RA-D₃). The parentfragment MS/MS transitions of m/z 299.2→121.2 Da for (4R)-OH-RA and (4S)-OH-RA and m/z 300.2→226.2 Da for 4oxo-RA-D₃ were used. The data were analyzed using Analyst software, the 4-OH-RA concentration was plotted as a function of time. The concentration versus time data was log-linear for two minutes and only data up to two minutes was used. Points for which concentration was below limit of quantification of the assay (0.1nM) were not included in the analysis. The depletion rate constant was obtained from the log-linear fit to the equation: $C = C_0 e^{-k_{dep}t}$ in which C equals 4-OH-RA enantiomer concentration at a given time t, C_0 the initial concentration of 4-OH-RA enantiomers and k_{dep} the

depletion rate constant as described previously (25). The K_m was obtained using the depletion data according to equation 1 (27),

$$k_{dep} = k_{dep,\max} \times (1 - \frac{[S]}{[S] + K_m}) \tag{1}$$

in which the substrate concentration [S] was corrected for depletion during the incubation (25). The maximum efficiency of depletion, the intrinsic clearance (V_{max}/K_m) , was calculated as $k_{dep,max}$ divided by the protein concentration as described (25). All nonlinear fits were done using GraphPad Prism v.5 (La Jolla, CA) and values are reported as mean \pm standard error.

The kinetics of the formation of 4-oxo-RA and 4,16-OH₂-RA were analyzed from (4R)-OH-RA and (4S)-OH-RA incubations respectively using identical LC-MS conditions as described above. 2 pmoles of CYP26A1 and 4 pmoles of P450 reductase were incubated with 5-150 nM of each enantiomer in 1 mL of potassium phosphate (100 mM, pH 7.4) buffer, and samples were extracted using ethyl acetate. For 4-oxo-RA quantification a standard curve using a 4oxo-standard was used and formation velocity measured. The formation of 4,16-OH₂-RA from (4S)-OH-RA was determined using relative quantification of 4,16-OH₂-RA peak height to internal standard ratio as a function of (4S)-OH-RA concentration.

The affinity (K_d) of the 4-OH-RA enantiomers to CYP26A1 was determined by fitting the Morrison equation (tight binding equation, equation 2) to the data as previously described for *at*RA binding to CYP26A1 (25).

$$V = V_{\max} \bullet \frac{([E] + [S] + K_m) - \sqrt{([E] + [S] + K_m)^2 - 4[E][S]}}{2[E]}$$

Significance of differences between determined kinetic parameters for the two enantiomers were evaluated using the Z-test and a p-value <0.05 was considered significant.

Chemical synthesis- The overall pathway for synthesis of 4-OH-RA enantiomers from methyl 4-oxo-retinoate is shown in Figure 1. The synthesis of the 4dimethylaminocinnamoate esters of methyl 4-OH-retinoate for CD spectroscopy is also shown. All syntheses are described in detail in supplemental data.

Assignment of absolute stereochemistry using CD spectroscopy- CD samples were prepared by dissolving weighed amounts of 4-dimethylaminocinnamoate esters (Figure 1) of the enantiomeric methyl 4hydroxyretinoates in acetonitrile to make 200 µM solutions (100 µg/ml). Spectra were recorded at 25°C on a JASCO J715 spectropolarimeter (JASCO Corporation, Tokyo, Japan) using a 0.10 cm path length cell with a nitrogen flow rate of 4 L/min. The wavelength and degree ellipticity scales were calibrated using a reference (1S)-(+)-10-camphorsulfonic acid ammonium salt (ACS) sample assuming that the ACS maximum corresponds to $[\Theta]_{290.5} = +7910$ (28). To minimize the effects of a possible photo-isomerization, only a single scan for each spectrum was collected at a scan rate of 100 nm/min with a 2 nm band width and a 0.2 nm step resolution over the wavelength range of 200-500 nm. The collected spectra were trimmed at a dynode voltage of 650 V (where required) prior to baseline subtraction (acetonitrile) and computationally smoothed using a two point fast Fourier transformation filter function included within (FFT filter) JASCO software (Spectra Manager 1.53.04). The raw ellipticity data (mdeg) were normalized by dividing them by the UV-Vis absorbance of the solutions at λ_{max} (356 nm).

Generation and validation of a CYP26A1 Homology Model- A CYP26A1 homology model was made using Modeller (29,30). The homology model was built using the

amino acid sequence of human CYP26A1 (NCBI Sequence No. NP 000774.2). Two cytochrome P450 X-ray crystal structures, cyanobacterial CYP120A1 (PDB ID: 2VE3 (31)) with *at*RA bound and mammalian CYP2C8 (PDB ID: 2NNH, (32)) with two 9cis-RAs bound, were used as structural templates. The CYP120A1 structure and the homology model were aligned and heme and atRA in the CYP120A1 structure were roughly docked to the homology model using PyMOL v1.2 (DeLano Scientific LLC, Palo Alto, CA, USA). To model the predominant structure in solution, molecular dynamics (MD) simulations were performed of the complex using GROMACS Version 4.07 (33). The topology files were modified to reflect the cysteinyl ligation as described previously (34,35). atRA was used to form the active site of the homology model of The CYP26A1. atRA molecule was obtained from PubChem (Compound Identifier CID 444795), and the protein was energy minimized by steepest descent approach using the MMFF94 force field (36) in Avogadro (Version 1.01). Since the primary site of metabolism is at the C-4 carbon, a time-averaged distance restraint of 3.4 and 7.4 Å was applied between the heme iron and this carbon. The complex was immersed in a simulated water box with 120 Å sides and ~50,000 waters, corresponding to roughly twice the length of the diagonal of the protein, or ~ 50 Å. Next, the complex was energy minimized by the method of steepest descent in order to remove van der Waals contact between overlapping waters and the amino acids of the protein. The simulations were run with Berendsen temperature and pressure coupling (37) at 300K, using the GROMOS 53a6 force field (38,39) and periodic boundary conditions in all directions. Electrostatics of the system were measured using the particle-mesh Ewald method (40). The MD simulation reached an equilibrium at >10 ns, but was

continued to 18.75 ns. The root mean square deviation (RMSD) of the backbone over the course of the simulation is shown in Supplemental Figure S1. The structure at the 18.75 ns time point was energy minimized by method of conjugate gradient energy and steepest descent minimization methods. The secondary structure assignments of this CYP26A1 homology model are shown in supplemental Table S1.

The CYP26A1 homology model with atRA restrained at C-4 was validated as described for other homology models of CYP26A1 (41-43) and the results are presented in supplemental Table S2. The backbone ϕ and ψ angles of the homology model were evaluated from Ramachandran plot obtained on the RAMPAGE server (http://mordred.bioc.cam.ac.uk/~rapper/ram page.php). The Ramachandran plot is shown Supplemental in Figure S2. The compatibility of the homology models threedimensional fold with the amino acid sequence was compared using Verify 3D (44). The program ERRAT was used to non-bonded analyze the interactions between different atom types (45). The quality of the homology model was overall better than previously built homology models (41-43).

Molecular Docking of atRA to CYP3A4. atRA was docked into the active site of CYP3A4 using Autodock Vina 1.1.1 (46). CYP3A4 To sample known the conformations, atRA was docked into the published X-ray crystal structures of the enzyme (PDBID: 2J0D (47), 3NXU (48), 3TJS (49), 1TQN (50), 3UA1 (49), 2V0M (47), 1W0E (51), 1W0F(51) and 1W0G (51)). AutoDockTools 1.4.6 (The Scripps Research Institute, La Jolla, CA) was used to put Gasteiger charges on the homology model and atRA. During the simulation, the protein was kept rigid and the carboxylic acid group of atRA was allowed to rotate. A box centered 10 Å away from the heme iron

with 20 Å sides was searched with the software. The maximum number of potential binding sites was set to 10. Binding sites with ~100 fold weaker binding affinity (i.e. 3 kcal/mol) than the tightest binding site were excluded as potential binding sites. The dissociation constant (K_d) was calculated for comparative purposes from the free energy (ΔG) in kcal mol⁻¹ using the $K_d = e^{\frac{AO}{RT}}$ where T is the equation: temperature in K and R is the gas constant in kcal $mol^{-1} K^{-1}$.

RESULTS

Separation of the 4-OH-RA enantiomers and stereoselective formation of 4-OH-RA by CYP26A1- A method for the separation of 4-OH-RA enantiomers using a Chiralcel OD-RH column was developed, and the separation of (4S)- and (4R)-OH-RA is shown in Figure 2a. To determine whether formation of 4-OH-RA by CYP26A1 is stereoselective, atRA was incubated with recombinant human CYP26A1 microsomes. A chromatogram of an incubation of *at*RA with CYP26A1 is shown in Figure 2b. CYP26A1 formed preferentially a single 4-OH-RA enantiomer. Other hydroxylation products were also detected in the CYP26A1 incubations that eluted after the 4-OH-RA enantiomers (Figure 2b), as previously reported (11,25). Based on previous studies (15) these products include 18-OH-RA and 16-OH-RA.

Determination of absolute stereochemistry of 4-OH-RA enantiomers- To determine the absolute stereochemistry of the predominant 4-OH-RA formed by CYP26A1, authentic standards of the (4S)- and (4R)-OH-RA enantiomers were synthesized (Figure 1) from 4-oxo-RA ester. Diborane (dimethyl sulfide) reduction in the presence of the methylated (S)- and (R)-Corey-Bakshi-Shibata (CBS)-oxazaborolidine catalysts (52), yielded the enantiomeric methyl (4S)and (4R)-OH-retinoates. The corresponding free acids were obtained by hydrolysis of the methyl esters with aqueous methanolic KOH, followed by acidification with citrate buffer (pH=6). The enantiomeric excess (ee %) of the 4-OH-RA enantiomers was determined using chiral HPLC. The enantiomeric excesses (ee %) of the synthesized (4S)and (4R)-OH-RA were 95% and 96%. enantiomers respectively (Figure 2c and 2d). The retention times of the synthetic standards show that CYP26A1 forms predominantly the (4S)-OH-RA.

To confirm the absolute stereochemistry of the products, the 4-hydroxyl group of each methyl retinoate enantiomer was coupled to the 4-(dimethylamino)cinnamoyl chromophore (Figure 1), and the exciton circular dichroism (CD) spectra of the 4-(dimethylamino)cinnamoate esters were obtained for the coupled products (Figure 3). The CD-spectra are mirror images of each other and show exciton split CD Cotton effects. For the (4R)-enantiomer, a negative first (longer wave length) and positive second Cotton effects were expected, since the 4-(dimethylamino)cinnamoyl and the pentaenacyl chromophores constitute a counterclockwise screw (Figure 3), while for the (4S)-enantiomer the opposite Cotton effects are expected (53). The obtained CDspectra were compared to the CD spectra of related 4-(dimethylamino)cinnamoyl esters of (4S)- and (4R)-OH-retinal (23) and the absolute configuration of the 4-OH-RA enantiomers confirmed. These data show hydroxylates that CYP26A1 at RA predominantly to the (4S)-OH-RA.

The Michaelis-Menten kinetic values of (4S)-OH-RA formation by CYP26A1 were determined (Supplemental Figure S3). The k_{cat} for (4S)-OH-RA formation was 2.1 ± 0.2 pmol/min/pmol P450 and K_m 10 \pm 6 nM. The K_m and k_{cat} of (4R)-OH-RA formation could not be determined due to the very low formation of this enantiomer and the lack of

concentration dependence in the formation (Supplemental Figure S3).

Stereoselectivity in 4-OH-RA formation by other P450 isoforms- The stereoselective formation of 4-OH-RA enantiomers by CYP3A4, CYP3A5, CYP3A7 and CYP2C8 was determined, as these enzymes have been previously shown to metabolize atRA in human liver. The chromatograms of the separation of the products formed are shown in Supplemental Figure S4. The other P450 enzymes were much less stereoselective in 4-hydroxylation of the atRA than CYP26A1. CYP3A4 formed (4R)-OH-RA and (4S)-OH-RA in approximately 1:1 ratio with equal K_m and k_{cat} values (Table 1). CYP3A5 formed (4R)-OH-RA twice as (4S)-OH-RA, efficiently as whereas CYP3A7 formed (4S)-OH-RA nearly twice as efficiently as (4R)-OH-RA (Table 1). The determined kinetic constants summarized in Table 1 show that stereoselective product ratios are mainly due to different k_{cat} values and not differences in K_m for formation of the (4S)- and (4R)-OH-RA.

Metabolism of 4-OH-RA enantiomers by CYP26A1- Racemic 4-OH-RA is a substrate of CYP26A1, and several sequential metabolites are formed from 4-OH-RA by CYP26A1 (15). Mass spectrometric analysis of the metabolic products formed from (4S)-OH-RA showed that the dihydroxylated product, 4,16-OH₂-RA, was the predominant metabolite formed from (4S)-OH-RA (Figure 4) and 4-oxo-RA was a minor metabolite. In contrast, 4-oxo-RA was the major product formed from (4R)-OH-RA along with multiple dihydroxylated metabolites including 4,16-OH₂-RA, 4,18-OH₂-RA, 4-oxo-16-OH-RA and 4-oxo-18-OH-RA. These products were also detectable from (4S)-OH-RA but were quantitatively minor (Figure 4). The identification of the metabolites was similar to those shown previously from racemic 4-OH-RA (15).

To determine the affinity of (4S)-OH-RA (4R)-OH-RA to CYP26A1, both and enantiomers were incubated with CYP26A1 and the formation of 4-oxo-RA from (4R)-OH-RA and 4,16-OH₂-RA from (4S)-OH-RA was measured as a function of 4OH-RA concentration (Figure 5a and b). Although the K_m value for (4S)-OH-RA (37.4 \pm 9.7 nM) was lower than that for (4R)-OH-RA $(45.8 \pm 12.3 \text{ nM})$, the K_m values were not significantly different from each other (p > p)0.25). The k_{cat} value for 4-oxo-RA formation from (4R)-OH-RA was 1.3 11.3 ± pmol/min/pmol P450.

To determine the catalytic efficiency of metabolizing 4-OH-RA CYP26A1 in enantiomers substrate depletion experiments were conducted. When (4S)-OH-RA and (4R)-OH-RA were incubated with CYP26A1 at 2.5 nM concentrations (<<K_m) depletion (4S)-OH-RA the of was significantly faster (p<0.005, $k_{dep}=1.8 \pm 0.5$ 1/min) than that of (4R)-OH-RA ($k_{dep}=0.6 \pm$ 0.02 1/min) (Figure 5). To further confirm the different kinetics of (4R)-OH-RA and (4S)-OH-RA depletion by CYP26A1 the depletions rates were analyzed at different concentrations. The depletion curves as well as the relationship between k_{dep} and 4-OH-RA concentration are shown in Figure 5e and f. The (4S)-OH-RA had significantly higher (p < 0.005) intrinsic clearance (1.4 \pm 0.1 mL/min/pmol P450) than (4R)-OH-RA $(0.7 \pm 0.1 \text{ mL/min/pmol P450})$. The affinity of (4S)-OH-RA (K_m 5.2 ± 1.3 nM) was not significantly different from that of (4R)-OH-RA (K_m 11.0 ± 5.2 nM).

Homology model of atRA bound CYP26A1 and Molecular Docking of atRA to CYP3A4-To explore the stereoselectivity in 4-OH-RA formation by CYP26A1 in comparison to CYP3A4, a homology model of CYP26A1 with *at*RA in the active site was constructed and energy minimized. *at*RA was also docked to the CYP3A4 active site. Figure 6a and 6b show the orientation of atRA in the CYP26A1 active site.

According to the model of atRA bound with CYP26A1, the β -ionone ring is positioned over the heme allowing oxidation of C4 as well as C18 and C16. The residues surrounding the β -ionone ring (F299, W112, L120, T304, and S126, Figure 6a and 6b) position the (4S)-hydrogen 1.5 Å closer to the heme than (4R)-hydrogen (4S-hydrogen distance 4.6 Å, (4R)-hydrogen distance 6.1 Å). The distance between C-4 and the heme iron was 5.6 Å. Overall the CYP26A1 active site shown in the model is small and consists of a network of hydrophobic residues that surround the nonatetraene chain of atRA. The nonatetraene chain of *at*RA directly interacts with several residues, including F84, W112, P113, V116, F374, and the hydrophobic parts of E303 and V370. The terminal carboxylic acid group of atRA interacts with R64, the positively charged residue in the active site.

To investigate the potential binding orientations of atRA within the CYP3A4 active site, atRA was docked in the published CYP3A4 crystal structures (Supplemental Figure S5). atRA was found in a number of orientations within the CYP3A4 active site as shown in Figure 6c and 6d. The distances between the heme iron and the hydrogen atoms at C-4 varied between 3.1 and 16.5 Å. The average distance was not different for (4S) and (4R) position (Table 2), in agreement with the similar rates of formation of (4R)- and (4S)-OH-RA by CYP3A4. Consistent with a large flexible active site of CYP3A4, the predicted affinity of the preferred orientation of atRA within the CYP3A4 active site varied 50-fold among the known crystal structures. The average affinity of $2.5 \,\mu\text{M}$ is similar to the experimentally measured K_m of 3 µM.

The orientation of *at*RA docked in the 1TQN crystal structure of CYP3A4 (Figure

6c and 6d) corresponds best to the average orientation of atRA in the different CYP3A4 structures. In this orientation, the β -ionone ring is located between residues R105, F108, I120, F215 and S119 positioning the ring in an angle that allows hydrogen atom abstraction from both the pro-S and pro-R position. The orientation of the β -ionone ring within the CYP3A4 active site in all structures (Supplemental Figure S5) has the C16 located away from the heme, which is consistent with the lack of formation of the 16-OH-RA by CYP3A4. The nonatetrene chain of *at*RA interacts with hydrophobic residues, F215, M371, L482, L483 and I369, in addition to the hydrophobic regions of R212 and T309 in the atRA docked 1TQN structure. The carboxylic acid group of atRA hydrogen bonds with S312 and E308. Repulsion from the hydrophilic residues within the active site might explain the large differences in the *at*RA orientations between the docked structures (Table 2).

DISCUSSION

of physiological effects RA The demonstrate high stereoselectivity, as atRA is believed to be the biologically active geometric isomer with less activity residing in the 13-cis-RA, 9-cis-RA and 9,13-dicis-RA stereoisomers. Generally, atRA has a higher affinity for many proteins such as RARs, CYP26A1 and CRABPs than the other RA isomers (16,26,54). However, the stereoselective metabolism of atRA and the role of stereoselectivity in the activity and biological fate of the metabolites have not been previously reported. This study shows for the first time that the hydroxylation of atRA by CYP26A1 is highly stereoselective. In contrast, the P450 enzymes that are not believed to be critical in *at*RA metabolism, CYP3A4, CYP3A5, CYP3A7 and CYP2C8, showed limited stereoselectivity suggesting that this is an inherent property of the enzymes that evolved to mediate *at*RA homeostasis.

Despite the fact that CYP26A1 forms preferentially (4S)-OH-RA, both 4-OH-RA enantiomers are good substrates of CYP26A1. This is plausible as the (4R)-OH-RA can be formed by the fetal liver CYP3A7, and by CYP3A4, CYP3A5 and CYP2C8 in the adult liver, and hence an elimination pathway for this enantiomer is also needed. However, the metabolism of 4-OH-RA by CYP26A1 was steresoselective with (4S)-OH-RA having significantly higher (p<0.005) intrinsic clearance than (4R)-OH-RA. While the K_m -value for (4S)-OH-RA depletion was consistently lower than that of (4R)-OH-RA the K_m values enantiomers between the were not significantly different. As such, the greater CL_{int} of (4S)-OH-RA is likely due to higher k_{cat} for the formation of the diol metabolite observed from (4S)-OH-RA than for the formation of 4-oxo-RA from the (4R)-OHenantiomer. Interestingly, as shown before for metabolism of atRA by CYP26A1, the K_m -values measured via product formation were higher than those measured via substrate depletion. This could, in part be due to the fact that the determination of the affinity via product formation allows correction for the depletion of free substrate due to binding to CYP26A1. The Clint and K_m values obtained for the 4-OH-RA enantiomers were similar to the Clint values obtained for 4-OH-RA formation and atRA depletion by CYP26A1 (15,25).

Different metabolites were formed from (4S)- and (4R)-OH-RA by CYP26A1, suggesting that the binding orientations of the two enantiomers in CYP26A1 active site are different. The profile of metabolites formed from (4S)-OH-RA by CYP26A1 is similar to that observed following incubations of *at*RA with CYP26A1, whereas the products formed from (4R)-OH-RA do not agree well with the product

profile from atRA (15). These results support the finding that CYP26A1 metabolizes atRA predominantly to (4S)-OH-RA, which is sequentially metabolized to 4,16-OH₂-RA product. In addition, the fact that only 4,16-OH₂-RA was formed from (4S)-OH-RA suggests that the other diols observed in atRA incubations with CYP26A1 are formed by 4-hydroxylation of the primary metabolites 18-OH-RA and 16-OH-RA. These data also suggest that in vivo 4-oxo-RA is formed via different enzymatic pathway from *at*RA, and not by CYP26A1. The high binding affinity of (4S)-OH-RA determined here also partially explains the observed non-dissociative metabolism of atRA bv CYP26A1 (25).Whether metabolism of 4-OH-RA by UGT enzymes and by the enzymes forming 4-oxo-RA is also stereoselective is currently not known.

The stereoselectivity of hydroxylation of atRA by CYP26A1 offers a unique opportunity to enhance our understanding of the molecular interactions between atRA and CYP26A1. to refine and the understanding of the structure of the CYP26A1 active site. The stereoselective formation of (4S)-OH-RA by CYP26A1 likely requires that the hydroxyl group be delivered from the si-face of the molecule to give (4S)-OH-RA. This is well illustrated in the homology model of CYP26A1, which shows a very well defined niche for atRA within the CYP26A1 active site and a distinct orientation of the β -ionone ring above the plane of the heme. The orientation of atRA within the CYP26A1 active site is consistent with stereoselective hydrogen atom abstraction from the pro-(S)-position and subsequent hydroxyl radical rebound. P450 mediated hydroxylations usually occur with retention of the stereochemistry at the reacting carbon, although occasionally products arising from both retention and inversion are reported (55).

In terms of the active site residues, the presented homology model is in good agreement with previously reported homology models of CYP26A1 (41-43). The previous models are also consistent with the stereoselective 4S hydroxylation of atRA. The presented model also explains both the stereoselectivity of 4-hydroxylation of atRA and the observed lack of regioselectivity in hydroxylation (15,26). It shows that the hydrogen atoms in C16 and C18 lie in a plane above the heme together with the pro-S hydrogen atom at C4. As such, the model suggests that hydroxylation at the C16 position would also be stereoselective as only one of the gem-dimethyl groups is close to the heme. The inferred limited mobility of atRA within the CYP26A1 active site is in contrast with the apparent greater mobility within the CYP3A4 active site. The multiple binding modes found for atRA with the CYP3A4 structures together with the similar average distances of the pro-S and pro-R hydrogen atoms is in agreement with the observed equal rates of (4S)-OH-RA and (4R)-OH-RA products formed by CYP3A4.

In summary, this study reports for the first time the synthesis and the determination of the absolute configuration of 4-OH-RA enantiomers and shows that CYP26A1 forms the (4S)-OH-RA stereoselectively. The observed product stereoselectivity and metabolism of both 4-OH-RA enantiomers by CYP26A1 will be useful in better modeling of CYP26A1 and aid in the structural design of novel CYP26A1 inhibitors as therapeutic agents. These results show that CYP26A1 accepts various biologically active retinoids as substrates. but has a conserved preference for the (4S)-OH-RA enantiomer over (4R)-OH-RA. These results show that the two 4-OH-RA enantiomers are physiologically distinct due to their different formation and elimination kinetics resulting in likely different cellular

exposures to these enantiomers and formation of different downstream active metabolites such as 4-oxo-RA. Further studies are needed to determine the role of stereoselectivity in the activity of the 4-OH-RA enantiomers and in the formation of 4oxo-RA from the individual stereoisomers.

Acknowledgements. This work was supported by NIH grants R01-GM081569,

REFERENCES

- 1. Blomhoff, R., and Blomhoff, H. K. (2006). *J. Neurobiol.* **66**, 606-630
- Jacobs, S., Lie, D. C., DeCicco, K. L., Shi, Y., DeLuca, L. M., Gage, F. H., and Evans, R. M. (2006). *Proc. Natl. Acad. Sci. U S A* 103, 3902-3907
- 3. Manolescu, D. C., Sima, A., and Bhat, P. V. (2010). *J. Nutr.* **140**, 311-316
- 4. Altucci, L., Leibowitz, M. D., Ogilvie, K. M., de Lera, A. R., and Gronemeyer, H. (2007). *Nat. Rev. Drug. Discov.* **6**, 793-810
- Samokyszyn, V. M., Gall, W. E., Zawada, G., Freyaldenhoven, M. A., Chen, G., Mackenzie, P. I., Tephly, T. R., and Radominska-Pandya, A. (2000). J. Biol. Chem. 275, 6908-6914
- 6. Nadin, L., and Murray, M. (1999). *Biochem. Pharmacol.* **58**, 1201-1208
- 7. McSorley, L. C., and Daly, A. K. (2000). *Biochem. Pharmacol.* **60**, 517-526
- 8. Marill, J., Cresteil, T., Lanotte, M., and Chabot, G. G. (2000). *Mol. Pharmacol.* **58**, 1341-1348
- 9. Eckhoff, C., and Nau, H. (1990). J. Lipid Res. **31**, 1445-1454
- Arnold, S. L., Amory, J. K., Walsh, T. J., and Isoherranen, N. (2011). J. *Lipid Res.* 53, 587-598

R01-GM081569-S1 and GM054995-16. The authors wish to thank Dr. Alex Zelter and Dr. Jayne E. Thatcher for their assistance in enzyme expression, preparation of microsomes and conduct of preliminary experiments, Dr. David R. Goodlett for use of his Linux cluster for the MD simulations and Dr. Justin Lutz for his assistance in obtaining the accurate mass measurements.

- White, J. A., Beckett-Jones, B., Guo, Y. D., Dilworth, F. J., Bonasoro, J., Jones, G., and Petkovich, M. (1997). *J. Biol. Chem.* 272, 18538-18541
- White, J. A., Ramshaw, H., Taimi, M., Stangle, W., Zhang, A., Everingham, S., Creighton, S., Tam, S. P., Jones, G., and Petkovich, M. (2000). *Proc. Natl. Acad. Sci. U S A* 97, 6403-6408
- 13. Thatcher, J. E., Zelter, A., and Isoherranen, N. (2010). *Biochem. Pharmacol.* **80**, 903-912
- 14. Duester, G. (2008). *Cell* **134**, 921-931
- Topletz, A. R., Thatcher, J. E., Zelter, A., Lutz, J. D., Tay, S., Nelson, W. L., and Isoherranen, N. (2012). *Biochem. Pharmacol.* 83, 149-163
- 16. Idres, N., Marill, J., Flexor, M. A., and Chabot, G. G. (2002). *J. Biol. Chem.* **277**, 31491-31498
- Reynolds, N. J., Fisher, G. J., Griffiths, C. E., Tavakkol, A., Talwar, H. S., Rowse, P. E., Hamilton, T. A., and Voorhees, J. J. (1993). *J. Pharmacol. Exp. Ther.* 266, 1636-1642
- van der Leede, B. M., van den Brink, C. E., Pijnappel, W. W., Sonneveld, E., van der Saag, P. T., and van der Burg, B. (1997). *J. Biol. Chem.* 272, 17921-17928

- 19. Sonneveld, E., van den Brink, C. E., Tertoolen, L. G., van der Burg, B., and van der Saag, P. T. (1999). *Dev. Biol.* 213, 390-404
- 20. Langton, S., and Gudas, L. J. (2008). Dev. Biol. **315**, 331-354
- Niederreither, K., Abu-Abed, S., Schuhbaur, B., Petkovich, M., Chambon, P., and Dolle, P. (2002). *Nature Genet.* 31, 84-88
- Achkar, C. C., Derguini, F., Blumberg, B., Langston, A., Levin, A. A., Speck, J., Evans, R. M., Bolado, J., Jr., Nakanishi, K., Buck, J., and Gudas, L. J. (1996). Proc. Natl. Acad. Sci. USA 93, 4879-4884
- Katsuta, Y., Ito, M., Yoshihara, K., Nakanishi, K., Kikkawa, T., and Fujiwara, T. (1994). *J. Org. Chem.* 59, 6917-6921
- Moise, A. R., Dominguez, M., Alvarez, S., Alvarez, R., Schupp, M., Cristancho, A. G., Kiser, P. D., de Lera, A. R., Lazar, M. A., and Palczewski, K. (2008). J. Am. Chem. Soc. 130, 1154-1155
- Lutz, J. D., Dixit, V., Yeung, C. K., Dickmann, L. J., Zelter, A., Thatcher, J. E., Nelson, W. L., and Isoherranen, N. (2009). *Biochem. Pharmacol.* 77, 258-268
- Thatcher, J. E., Buttrick, B., Shaffer, S. A., Shimshoni, J. A., Goodlett, D. R., Nelson, W. L., and Isoherranen, N. (2011). *Mol. Pharmacol.* 80, 228-239
- 27. Obach, R. S., and Reed-Hagen, A. E. (2002). Drug. Metab. Dispos. 30, 831-837
- 28. Takakuwa, T., Konno, T., and Meguro, H. (1985). *Anal. Sci.* **1**, 215-218
- 29. Eswar, N., Eramian, D., Webb, B., Shen, M. Y., and Sali, A. (2008). *Methods Mol. Biol.* **426**, 145-159

- 30. Fiser, A., and Sali, A. (2003). *Methods Enzymol.* **374**, 461-491
- Kuhnel, K., Ke, N., Cryle, M. J., Sligar, S. G., Schuler, M. A., and Schlichting, I. (2008). *Biochemistry* 47, 6552-6559
- Schoch, G. A., Yano, J. K., Sansen, S., Dansette, P. M., Stout, C. D., and Johnson, E. F. (2008). *J. Biol. Chem.* 283, 17227-17237
- Berendsen, H. J. C., van der Spoel, D., and Drunen, R. (1995). Comput. Phys. Commun 91, 43-56
- 34. Autenrieth, F., Tajkhorshid, E., Baudry, J., and Luthey-Schulten, Z. (2004). J. Comput. Chem. 25, 1613-1622
- Oda, A., Yamaotsu, N., and Hirono, S. (2005). J. Comput. Chem. 26, 818-826
- 36. Halgren, T. A. (1996). J. Comput. Chem. 17, 490-519
- Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W., DiNola, A., and Haak, J. R. (1984). *J. Chem. Phys.* 81, 3684-3690
- 38. Oostenbrink, C., Soares, T. A., van der Vegt, N. F., and van Gunsteren, W. F. (2005). *Eur. Biophys. J.* 34, 273-284
- Oostenbrink, C., Villa, A., Mark, A. E., and van Gunsteren, W. F. (2004).
 J. Comput. Chem. 25, 1656-1676
- Darden, T., York, D., and Pedersen, L. (1993). J. Chem. Phys. 98, 10089-10092
- Gomaa, M. S., Yee, S. W., Milbourne, C. E., Barbera, M. C., Simons, C., and Brancale, A. (2006). *J. Enzyme Inhib. Med. Chem.* 21, 361-369
- 42. Karlsson, M., Strid, A., Sirsjo, A., and Eriksson, L. A. (2008). J. Chem. Theory Comput. 4, 1021-1027
- 43. Ren, J. H., Xiong, X. Q., Sha, Y., Yan, M. C., Lin, B., Wang, J., Jing,

Y. K., Zhao, D. M., and Cheng, M. S. (2008). *Molecular Simul.* **34**, 337-346

- 44. Eisenberg, D., Luthy, R., and Bowie,
 J. U. (1997). *Methods Enzymol.* 277, 396-404
- 45. Colovos, C., and Yeates, T. O. (1993). *Protein Sci.* **2**, 1511-1519
- 46. Trott, O., and Olson, A. J. (2010). *J. Comput. Chem.* **31**, 455-461
- 47. Ekroos, M., and Sjogren, T. (2006). *Proc. Natl. Acad. Sci. U. S. A.* **103**, 13682-13687
- 48. Sevrioukova, I. F., and Poulos, T. L. (2012). *J. Biol. Chem.* **287**, 3510-3517
- Sevrioukova, I. F., and Poulos, T. L. (2010). Proc. Natl. Acad. Sci. U. S. A. 107, 18422-18427
- 50. Yano, J. K., Wester, M. R., Schoch, G. A., Griffin, K. J., Stout, C. D.,

and Johnson, E. F. (2004). J. Biol. Chem. 279, 38091-38094

- 51. Williams, P. A., Cosme, J., Vinkovic, D. M., Ward, A., Angove, H. C., Day, P. J., Vonrhein, C., Tickle, I. J., and Jhoti, H. (2004). *Science* 305, 683-686
- 52. Corey, E. J., Bakshi, R. K., and Shibata, S. (1987). *J. Am. Chem. Soc.* **109**, 5551-5553
- 53. Cai, G., Bozhkova, N., Odingo, J., Berova, N., and Nakanishi, K. (1993). J. Am. Chem. Soc. **115**, 7192-7198
- 54. Fiorella, P. D., and Napoli, J. L. (1991). J. Biol. Chem. 266, 16572-16579
- 55. Ortiz de Montellano, P. R. (2010). *Chem. Rev.* **110**, 932-948

Figures Legends

Figure 1. Synthesis of (+)-(4S)- and (-)-(4R)*-all-trans***-RA and the 4-dimethylaminocinnamoate esters of methyl 4-OH-retinoiate.** Reaction conditions were: (a) (R)-2-methyl-CBSoxazaborolidine ((R)-CBS), BH₃·S(CH₃)₂, THF, 16 hr, yield 85%. (b) (S)-2-methyl-CBSoxazaborolidine ((S)-CBS), BH₃·S(CH₃)₂, THF, 16 hr, yield 79%. (c) 1M KOH in water:MeOH (8:1) room temp, 4 hr; citrate buffer (pH 6) (d) 4-(dimethylamino)cinnamoyl-1H-1,2,4-tetrazole amide, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).

Figure 2. HPLC separation of the 4-OH-RA enantiomers and stereoselective formation of (4S)-OH-RA by CYP26A1. The 4-OH-RA enantiomers were separated from the racemic mixture using a Chiralcel OD-RH column (5 μ m, 2.1 x 150 mm) and a water-acetonitrile gradient as described in Experimental section. Panel (a) shows the separation of (4R)- and (4S)-OH-RA in a racemic mixture, and panel (b) shows the stereoselective formation of (4S)-OH-RA from *at*RA (200 nM) by CYP26A1 (5 pmol/mL). The determination of enantiomeric excess (ee) for the synthetic (-)-(4R)-OH-RA (ee 96.3%, rt 11.4 min) and (+)-(4S)-OH-RA (ee 95.1%, rt 9.8 min) and the identification of the two enantiomers is shown in panels (c) and (d).

Figure 3. Determination of the absolute configuration of 4-OH-RA enantiomers by exciton circular dichroism (CD) spectroscopy. CD spectra (top) of the 4-(dimethylamino)cinnamoyl esters of methyl (4S)- and (4R)-OH-retinoate in acetonitrile. The bottom panels show the structures of the 4-(dimethylamino)cinnamoyl esters. The UV-vis spectrum of the enantiomers is shown in green in the top panel.

Figure 4. Identification of the metabolites formed from (4S)-OH-RA (a) and (4R)-OH-RA (b) by CYP26A1. The MS/MS transitions monitored are shown next to each trace and the identified

metabolites are indicated for each peak. Incubations and analysis were carried out as described in the experimental section and metabolic products were identified as described previously (15).

Figure 5. Metabolism of (4S)-OH-RA (left panel) and (4R)-OH-RA (right panel) by

CYP26A1. The formation of specific metabolites was measured using (4S)-OH-RA (panel a) and (4R)-OH-RA (panel b) as substrates, and the K_m value determined according to equation 2. The relative formation rate of 4,16-OH₂-RA was quantified from peak height ratio whereas 4-oxo-RA formation was quantified using a standard curve. Error bars show the standard deviations of triplicate measurements for each point. Panels c and d show the depletion of (4S)-OH-RA and (4R)-OH-RA by CYP26A1 at 2.5 nM initial concentration (closed circles). The closed squres show the depletion of 4OH-RA enantiomers in no-enzyme control incubations. No NADPH controls were also done and they were identical to the no enzyme controls (not shown). Error bars show the standard deviation of triplicate incubations. Representative determinations of the concentration dependent depletion of (4S)-OH-RA and (4R)-OH-RA by CYP26A1 are shown in panels e and f, respectively. The depletion rates were measured at six different concentrations and the depletion rate constants determined (insets in panels e and f). All depletion experiments were conducted on multiple days and in triplicate on each day. Standard deviations for the individual measurements are shown by error bars. Equation 1 was fitted to the data of depletion constants as a function of 4-OH-RA concentration to determine the K_m and $k_{dep,max}$ of (4S)-OH-RA and (4R)-OH-RA depletion by CYP26A1. The kinetic values for (4S)-OH-RA were $K_m = 5.2 \pm 1.3$ nM and $k_{dep,max} = 2.9 \pm 0.3$ min⁻ ¹. For (4R)-OH-RA the values were $K_m = 11.0 \pm 5.2$ nM and $k_{dep,max} = 1.5 \pm 0.2$ min⁻¹.

Figure 6. The binding of atRA to CYP26A1 (a and b) and CYP3A4 (c and d). The

orientation of *at*RA within the energy minimized CYP26A1 homology model is shown from two different angles in panels a and b. In panels c and d, only the 1TQN X-ray crystal structure of

CYP3A4 is shown for clarity. The atRA molecule bound to the 1TQN X-ray crystal structure is highlighted, since it is roughly average from all the bound orientations which are shown semitransparent. Stick models of atRA (orange), interacting residues (green) and the heme (red) with a cartoon (gray) representation of protein structures in the background. Only the interacting amino acid side chains are shown.

Tables

	CYP3A4		CYP3A5		CYP3A7	
	(4S)-OH-RA	(4R)-OH-RA	(4S)-OH-RA	(4R)-OH-RA	(4S)-OH-RA	(4R)-OH-RA
K_m	4.7 ± 0.6	4.6 ± 1.1	6.0 ± 1.2	6.0 ± 1.1	3.5 ± 1.3	3.1 ± 0.6
(µM)						
k _{cat}	5.1 ± 0.2	5.3 ± 0.6	3.6 ± 0.2	7.0 ± 0.4	5.1 ± 0.6	2.7 ± 0.2
(pmol/min/pmol P450)						
k_{cat}/K_m	1.1	1.2	0.6	1.1	1.5	0.9
(µL/min/pmol P450)						

Table 1. Michaelis-Menten kinetic parameters for (4S)-OH-RA and (4R)-OH-RA formation by CYP3A isoforms

PDB ID	$K_d(\mu M)$	Distance of	Distance of
		4R-H from heme (Å)	4S-H from heme (Å)
1TQN	0.93	7.3	8.2
1W0E	0.93	5.3	6.3
1W0F	0.93	4.3	4.0
1W0G	3.00	4.0	5.3
2J0D	2.15	11.3	9.9
2V0M	0.30	16.5	16.4
3TJS	0.40	12.0	11.9
3UA1	13.52	3.1	3.5
3NXU	0.67	9.1	9.5
Average	2.54±3.97	8.1±4.2	8.3±3.9

Table 2. K_d and distance parameters for docking of atRA to the available Crystal Structures of *CYP3A4*.



R' = dimethylaminocinnamoyl

R' = dimethylaminocinnamoyl

Figure 2.



Figure 3



4-(Dimethylamino)cinnamoyl ester of methyl (4S)-OH-retinoate Clockwise orientation: positive chirality



4-(Dimethylamino)cinnamoyl ester of methyl (4R)-OH-retinoate Counterclockwise orientation: negative chirality

Figure 4









